Market Wrap Week 16: Speculative tech runs hot while a2 Milk tumbles

Xref Limited (ASX:XF1) topped the board with a weekly gain of 81.03%, after investors latched onto both strong recurring revenue growth and the launch of Xref.me, a verified digital resume product aimed at turning job applications into paid software traffic. Immutep (ASX:IMM) jumped 72.50% after winning US orphan drug status for eftilagimod alfa in soft tissue sarcoma. That matters because it can bring fee reductions, tax benefits and a period of market exclusivity if the drug is approved. Zip Co (ASX:ZIP) rose 26.29% after lifting FY26 cash earnings guidance and reporting fast growth in the US business. In plain terms, investors saw stronger profits and decided the turnaround still had room to run.

Growth names pulled buyers back in

Several of the week’s strongest movers came from smaller growth stocks where the news was easy to understand. Xref showed higher annual recurring revenue, lower operating costs and a new product that could bring in more paying users. WhiteHawk (ASX:WHK) rose 14.29% after buying Quixxi to move into AI governance, which means software that checks whether artificial intelligence systems are safe and properly controlled. Vinyl Group (ASX:VNL) completed its Val Morgan Digital deal, while Freelancer (ASX:FLN) pointed to record profit and a large NASA contract. Not every early jump held all week. In some names, traders bought the open and then sold into strength, so early gains faded by Friday.

Biotech moved on clear triggers

Healthcare stocks also had a strong run when the news had a direct commercial link. Telix Pharmaceuticals (ASX:TLX) announced a radiopharma partnership with Regeneron that included US$40 million upfront and possible milestone payments above US$2 billion. The stock reopened lower after the halt and slipped further, which suggests some holders took profit despite the size of the deal. BlinkLab (ASX:BB1) raised A$17.5 million to fund autism and ADHD trials, while AVITA Medical (ASX:AVH) posted interim wound-care data showing patients could reach skin grafting much sooner. Mesoblast (ASX:MSB) gained after securing rights to a new cell therapy targeting tool. In this part of the market, investors cared most about one thing: does the news make future sales or approval more likely?

Resources kept winning when the numbers were solid

Mining and energy names were busy again. Sovereign Metals (ASX:SVM) delivered one of the week’s most important studies, with Kasiya showing a pre-tax net present value of US$2.2 billion and a 25-year mine life. Net present value is a simple estimate of what a project may be worth today after adding future cash flow and discounting it back. Paladin Energy (ASX:PDN) climbed 15.49% after raising uranium output guidance. Solstice Minerals (ASX:SLS) gained 12.16% on strong copper-gold drilling, while Ora Banda Mining (ASX:OBM) added 11.19% after record production and cash flow. Investors were willing to pay up when a company either proved a project could make money or showed it was already pulling more cash out of the ground.

Gold names were especially active. Genesis Minerals (ASX:GMD) reported stronger cash and kept work moving on Tower Hill while preparing to close its Magnetic Resources deal. Magnetic Resources (ASX:MAU) stayed near flat as holders weighed the scheme terms. GoldArc Resources (ASX:GA8) rose 20.69% across a stream of updates because the story was simple: drilling kept finding grade and a partner agreed to fund development costs. That removed a common fear for small miners, namely having to raise fresh equity before first production.

Corporate deals kept coming

Mergers, takeovers and scheme votes remained a large part of the week’s newsflow. Insignia Financial (ASX:IFL) shareholders backed the A$3.3 billion CC Capital scheme. National Storage REIT (ASX:NSR) securityholders approved the Brookfield-GIC offer. African Gold (ASX:A1G) also won near-unanimous support for its sale to Montage Gold. Champion Iron (ASX:CIA) completed its US$300 million Rana Gruber acquisition to deepen its exposure to iron ore used in lower-emissions steelmaking. Yancoal Australia (ASX:YAL), by contrast, fell 6.79% even after unveiling its Kestrel acquisition. The deal is large, partly debt-funded and tied to coal prices, so some investors appear to have worried first about the size of the cheque rather than the longer-term prize.

The weakest spot was consumer guidance

The sharpest selling came in The a2 Milk Company (ASX:A2M), down 19.16%, after the company cut FY26 guidance. The issue was not weak demand. It said demand in China remained strong. The problem was supply delays, freight disruption and production bottlenecks, which meant it could not get enough product through the system. Investors usually react badly when a company says sales are there but cannot be booked on time. Lode Resources (ASX:LDR) fell 15.15% despite a maiden silver-antimony resource, suggesting the market had expected more after the stock’s earlier run. Memphasys (ASX:MEM) slipped 16.67% even as it posted first meaningful commercial sales, a sign that thinly traded small caps can still fall when buyers step back.

Elsewhere, AMP (ASX:AMP) improved platform flows and started a buyback, Life360 (ASX:360) extended its run after reporting its first full-year profit, and Michael Hill International (ASX:MHJ) gained on a cleaner retail strategy and a plan to resume dividends. Across the board, the market rewarded updates that came with hard figures, signed contracts or near-dated milestones. It was less forgiving when announcements raised fresh questions about delivery, debt or whether early excitement had run ahead of facts.